XML 48 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment and Related Information
 9 Months Ended
Mar. 31, 2015
Segment and Related Information
(6) Segment and Related Information

The Company’s business units have been aggregated into three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services. The research segment is focused on the discovery of genes, biomarkers and proteins related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The pharmaceutical and clinical services segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.

Segment revenue and operating income (loss) were as follows during the periods presented:

 

(In thousands)    Molecular
diagnostics		      Pharmaceutical &
clinical services		      Research      Total  

Three months ended March 31, 2015:

            

Revenue

    $ 172,978         7,007         —         $ 179,985   

Depreciation and amortization

      5,207         566         626         6,399   

Segment operating income (loss)

      55,198         (1,147 )       (18,311 )       35,740   

Three months ended March 31, 2014:

            

Revenue

    $ 176,191         6,733         —         $ 182,924   

Depreciation and amortization

      2,506         471         502         3,479   

Segment operating income (loss)

      70,815         (73 )       (15,455 )       55,287   

Nine months ended March 31, 2015:

            

Revenue

    $ 516,634         16,582         —         $ 533,216   

Depreciation and amortization

      15,176         1,465         1,748         18,389   

Segment operating income (loss)

      159,299         (3,941 )       (57,356 )       98,002   

Nine months ended March 31, 2014:

            

Revenue

    $ 565,335         24,115         —         $ 589,450   

Depreciation and amortization

      5,335         1,462         1,494         8,291   

Segment operating income (loss)

      266,794         2,816         (48,422 )       221,188   

 

     Three months ended
March 31,		      Nine months ended
March 31,		  
(In thousands)    2015      2014      2015      2014  

Total operating income for reportable segments

    $ 35,740       $ 55,287       $ 98,002       $ 221,188   

Interest income

      124         2,498         265         5,190   

Other

      (298 )       (442 )       1,117         (1,066 ) 

Income tax provision

      14,091         20,573         37,896         82,719   
  

 

 

     

 

 

     

 

 

     

 

 

  

Net income

 $ 21,475    $ 36,770    $ 61,488    $ 142,593